ReviewTherapeutics and clinical risk management2015

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.

David L Tucker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.